The OTIS Council brings together world leaders in oncology whose collective expertise enriches the scientific foundation of TD2 Oncology. This group includes some of the most respected minds in cancer drug development, each with decades of experience shaping how new therapies move from concept to clinical reality.
Aligned with TD2 Oncology’s leadership, the OTIS Council contributes scientific, strategic, and clinical insights to our programs. Their involvement infuses our work with modern scientific thinking in oncology, grounded in real world experience, a deep understanding of what drives meaningful therapeutic progress, with an unwavering focus on patient benefit.
The presence of the OTIS Council reinforces our commitment to being the oncologist-trusted CRO. Their insight adds valuable depth to our scientific approach and supports our teams as we continue to evaluate, design, and advance innovative oncology programs with clarity and confidence.
Role of the OTIS Council
Elevating Scientific Strategy
The council contributes deep scientific perspective that supports our approach to oncology drug development. Their insight helps shape thinking around mechanisms of action, translational rationale, early development planning, and clinical development strategies.
Grounding Decisions in Real-World Experience
Each member brings extensive hands-on knowledge from leading early phase to complex studies. Their experience informs how our team evaluates feasibility, identify key considerations, and approach development with a strong understanding of the clinical and regulatory landscape.
Strengthening Internal Review and Thinking
The Council provides high value input on emerging trends, evolving scientific standards, and strategic considerations across the rapidly evolving oncology landscape. These critical perspectives add depth to our expertise and enhance how we set innovative oncology drug programs up for success.
Supporting a Culture of Scientific Excellence
The OTIS Council contributes to the scientific mindset that defines TD2 Oncology’s unique approach. Their influence complements the expertise already present within our organization and supports continuous growth across scientific, clinical, and strategic domains.
Enhancing Sponsor Confidence
The insight of the OTIS Council strengthens the scientific foundation that anchors every program we support. Sponsors gain added confidence knowing that our approach is informed by leaders whose work has contributed to some of the most meaningful advances in oncology. Their involvement helps us recognize opportunities, anticipate challenges, and support each program with a deeply informed and forward-thinking perspective.
Meet the OTIS Council Members
Dr. Daniel D. Von Hoff
Daniel Von Hoff, MD, FACP is a medical oncologist and pioneering figure in oncology drug development, known for his leadership in bringing many FDA approved therapies to patients. His work spans innovative clinical trial design, early development strategy, and scientific guidance for programs across a broad range of solid tumors. With more than 800 publications and decades of contributions to cancer research, he is widely recognized for shaping the field and advancing transformative therapies into clinical practice.
Dr. Patricia M. LoRusso
Patricia LoRusso, DO, PhD (hc), FAACR is an internationally respected medical oncologist with deep expertise in early phase research and experimental therapeutics. She has directed more than 300 clinical trials and contributed to the development of several approved cancer therapies. Her work is highly regarded for bridging scientific discovery with clinical application, advancing innovative strategies, and supporting the evolution of modern oncology development.
Dr. Alex Spira
Alex Spira, MD, PhD, FACP is a medical oncologist with extensive experience in early phase development, immuno-oncology, and complex clinical trial execution. He has led hundreds of studies and contributes deep insight into translational strategy, therapeutic feasibility, and next generation development approaches. His expertise in first-in-human research and novel mechanisms informs strategic thinking across both scientific and clinical domains.
Dr. Timothy Yap
Timothy Yap MBBS, PhD, FRCP is a physician-scientist specializing in first-in-human and biomarker-driven oncology trials. His work focuses on targeted agents, DNA damage response inhibitors, and innovative immunotherapy combinations. As principal investigator on numerous phase I and II studies and author of more than 250 peer-reviewed publications, he brings a strong blend of scientific depth, translational insight, and clinical leadership to complex therapeutic development.
Dr. Ron Korn
Ron Korn, MD, PhD is a leader in oncologic imaging, radiotheranostics, and advanced imaging biomarkers. His experience includes more than 25 years in diagnostic radiology, nuclear medicine, PET imaging, and translational imaging analytics. He has played a key role in developing imaging strategies for clinical trials, integrating quantitative imaging, radiomics, and novel imaging endpoints to support therapeutic evaluation. His expertise strengthens understanding of how imaging advances can guide oncology development and inform decision making.
A Stronger Future for Oncology Development
The OTIS Council reflects our commitment to scientific leadership and innovation. Their collective expertise provides valuable scientific perspective across our teams and informs the foundation of every development program we support. By uniting pioneering minds in oncology, we continue to advance a more informed and strategically aligned approach to cancer therapy development.
